Abstract Library

#4110 The role of fibrosis markers in predicting decline in renal function in patients undergoing PRRT

Introduction: Renal impairment due to renal fibrosis is a potential side effect in NET-patients undergoing Peptide Receptor Radionuclide Therapy (PRRT). Fibrosis markers are small collagen formation - and degradation fragments that are measurable in circulation at very early stages of fibrosis formation.

Conference:

Presenting Author: Lau T

Authors: Lau T, Bossen L, Rasmussen D, Karsdal M, Genovese F,

Keywords: PRRT, Biomarker, Fibrosis Marker,

#3804 Wide molecular analysis of PanNET revealed that only MGMT promoter methylation seemed to correlate with Temozolomide response

Introduction: Temozolomide (TMZ) is an alkylating agent and is widely used in the treatment of PanNET. So far, only the MGMT status, defined by its immunohistochemical (IHC) expression or its promoter methylation, has been proposed as predictor of response to TMZ, but its value remains controversial.

Conference:

Presenting Author: Marinoni I

Authors: Cives M, Kirchner P, Palmirotta R, Lauricella E, de Mestier L,

Keywords: PanNET, Temozolomide, MGMT,

#3768 Predictive transcriptomic signature of response to axitinib in patients with advanced NETs included in the randomized, double-blind, placebo-controlled AXINET trial (GETNE 1107)

Introduction: Axitinib in combination with Octreotide LAR significantly improved ORR (13.2 vs 3.2%, OR 4.58, p=0.0045) and PFS (16.6 vs 9.9m, HR 0.71, p=0.017) per central blinded radiological assessment, as compared to placebo and SSA, in 256 patients with EP-NETs included in the AXINET trial (Garcia-Carbonero et al, ESMO 2021). The magnitude of the benefit, however, was limited.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Carretero C, Antón-Pascual B, Capdevila J, Benavent M,

Keywords: Axitinib, Tyrosine kinase inhibitor, predictive biomarker, signature,

#2916 Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus?

Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wetz C, Genseke P, Schatka I, Jann H, Rogasch J,

Keywords: Neuroendocrine Neoplasia, Asphericity, Everolimus, Prediction,

#2188 Predictive Markers of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)

Introduction: NET are relatively rare and up to still far from fully studied pathology. The frequency of NET GEP does not exceed 2% of all tumors of this localization.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Issaeva S, Khalimova Z, Safarova M, Gumarova A, Yuldashev A,

Keywords: gastroenteropancreatic neuroendocrine tumors, morphology, clinical,